Sugi Predict

Sugi Predict / Compounds / SCHEMBL15798317

SCHEMBL15798317

SCHEMBL15798317

O=c1[nH]c(=O)n(CCO)cc1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.45

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ PYGM P11217 3/20 0.45
▸ TK2 O00142 5/20 0.42
▸ P2RY2 P41231 1/20 0.40
▸ SLC28A1 O00337 1/20 0.40
▸ SLC28A2 O43868 1/20 0.40
▸ SLC29A1 Q99808 1/20 0.40
▸ SLC28A3 Q9HAS3 1/20 0.40
▸ SLC5A2 P31639 1/20 0.38
▸ LMNA P02545 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ TK1 P04183 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26235972 1.00 PYGM (0.45) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL15810682 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL15810684 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL19007490 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL17210982 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL18870659 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL15798586 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL30765011 0.90 PYGM (0.44) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL15798509 0.90 PYGM (0.47) PYGMTK2P2RY2SLC28A1SLC28A2
SCHEMBL12223730 0.88 PYGM (0.42) PYGMTK2P2RY2SLC28A1SLC28A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 556 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026106956-A1 DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN MERCK SHARP & DOHME LLC (US) 2026-05-21 — — WO disclosed
US-12629412-B2 Betacoronavirus mRNA vaccines MODERNATX, INC. (US) 2026-05-19 — — US disclosed
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF ADVANCED RNA VACCINE ARV TECH INC (US) 2026-05-14 — — US disclosed
US-12622960-B2 Varicella zoster virus (VZV) vaccine MODERNATX, INC. (US) 2026-05-12 — — US disclosed
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-23 — — US disclosed
EP-4727955-A1 CYSTEINE-SUBSTITUTED RSV-F PROTEINS GlaxoSmithKline Biologicals S.A. (BE) 2026-04-22 — — EP disclosed
EP-3458081-B1 POLYNUCLEOTIDES ENCODING CITRIN FOR THE TREATMENT OF CITRULLINEMIA TYPE 2 MODERNATX INC (US) 2026-04-15 — — EP disclosed
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES MODERNATX, INC. (US) 2026-04-09 — — US disclosed
US-20260091104-A1 NUCLEIC ACID VACCINES MODERNATX, INC. (US) 2026-04-02 — — US disclosed
US-12582609-B2 Cancer vaccines MODERNATX, INC. (US) 2026-03-24 — — US disclosed
EP-2931319-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF Moderna Therapeutics, Inc. (US) 2015-10-21 — — EP disclosed
EP-2918275-A1 Alternative nucleic acid molecules and uses thereof Roy, Atanu (US) 2015-09-16 — — EP disclosed
US-20150167017-A1 ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. 2015-06-18 — — US disclosed
WO-2015085318-A2 TARGETED ADAPTIVE VACCINES MODERNA THERAPEUTICS, INC. (US) 2015-06-11 — — WO disclosed
WO-2015058069-A1 COMPOSITIONS AND METHODS FOR TOLERIZING CELLULAR SYSTEMS MODERNA THERAPEUTICS, INC. (US) 2015-04-23 — — WO disclosed
WO-2015051214-A1 POLYNUCLEOTIDES ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR MODERNA THERAPEUTICS, INC. (US) 2015-04-09 — — WO disclosed
WO-2015048744-A2 POLYNUCLEOTIDES ENCODING IMMUNE MODULATING POLYPEPTIDES MODERNA THERAPEUTICS, INC. (US) 2015-04-02 — — WO disclosed
WO-2015038892-A1 POLYNUCLEOTIDE COMPOSITIONS CONTAINING AMINO ACIDS MODERNA THERAPEUTICS, INC. (US) 2015-03-19 — — WO disclosed
WO-2015034928-A1 CHIMERIC POLYNUCLEOTIDES MODERNA THERAPEUTICS, INC. (US) 2015-03-12 — — WO disclosed
WO-2014093924-A1 MODIFIED NUCLEIC ACID MOLECULES AND USES THEREOF MODERNA THERAPEUTICS, INC. (US) 2014-06-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260097110-A1 BETACORONAVIRUS mRNA VACCINES RNMT, RNGTT, METTL16 PYGM 2866/4885TK2 3633/4885P2RY2 3702/4885
US-12582609-B2 Cancer vaccines RNMT, MICA, NSUN2 PYGM 4875/4885TK2 2216/4885P2RY2 4869/4885
US-12629412-B2 Betacoronavirus mRNA vaccines RNMT, RNGTT, METTL16 PYGM 3025/4885TK2 3425/4885P2RY2 3465/4885
US-20260091104-A1 NUCLEIC ACID VACCINES RNMT, NSUN2, AMPD1 PYGM 4334/4885TK2 1560/4885P2RY2 2368/4885
US-20260108595-A1 BETACORONAVIRUS mRNA VACCINES RNMT, METTL16, NSUN2 PYGM 3499/4885TK2 4100/4885P2RY2 4218/4885
US-12622960-B2 Varicella zoster virus (VZV) vaccine NSUN2, RNMT, RNGTT PYGM 3599/4885TK2 1499/4885P2RY2 3465/4885
US-20260130985-A1 NUCLEIC ACID-BASED UNIVERSAL VACCINE AND METHODS OF USE THEREOF UPF1, NSUN2, CD4 PYGM 3513/4885TK2 2857/4885P2RY2 3072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.